ATNF - 180 Life Sciences Corp. Stock Price, Fair Value and News

2.00USD+0.01 (+0.50%)Market Closed

Market Summary

USD2.00+0.01

Market Closed

0.50%

ATNF Stock Price

View Fullscreen

ATNF RSI Chart

ATNF Valuation

Market Cap

1.7M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

64.42

EV/EBITDA

0.01

Price/Free Cashflow

-0.16

ATNF Price/Sales (Trailing)

ATNF Profitability

EBT Margin

-85888.10%

Return on Equity

15.6K%

Return on Assets

-379.03%

Free Cashflow Yield

-640.4%

ATNF Fundamentals

ATNF Revenue

Revenue (TTM)

25.9K

ATNF Earnings

Earnings (TTM)

-19.9M

Earnings Growth (Yr)

94.36%

Earnings Growth (Qtr)

88.05%

Breaking Down ATNF Revenue

Last 7 days

13.0%

Last 30 days

-4.8%

Last 90 days

900%

Trailing 12 Months

78.6%

How does ATNF drawdown profile look like?

ATNF Financial Health

Current Ratio

0.72

ATNF Investor Care

Shares Dilution (1Y)

332.43%

Diluted EPS (TTM)

-52.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	25.9K
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 180 Life Sciences Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 28, 2023	feldmann marc	acquired	-	-	135,377	-
Dec 15, 2023	woody james n.	bought	4,700	0.188	25,000	chief executive officer
Dec 15, 2023	feldmann marc	sold	-4,700	0.188	-25,000	-
Sep 04, 2023	gold lawrence marshall	acquired	-	-	21,455	-
Sep 04, 2023	marrone pamela g	acquired	-	-	22,388	-
Sep 04, 2023	mcgovern jr. donald a.	acquired	-	-	25,186	-
Sep 04, 2023	ray russell t	acquired	29,178	1.36	21,455	-
Jun 01, 2023	steinman lawrence	bought	22,068	1.226	18,000	-
May 31, 2023	mcgovern jr. donald a.	bought	11,470	1.147	10,000	-
May 19, 2023	mcgovern jr. donald a.	bought	5,800	1.16	5,000	-

Which funds bought or sold ATNF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 19, 2024	Level Financial Advisors, Inc.	sold off	-100	-21.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-19,093	10,216	-%
Feb 26, 2024	Virtu Financial LLC	added	404	7,000	16,000	-%
Feb 14, 2024	MSD Partners, L.P.	unchanged	-	-648	378	-%
Feb 14, 2024	Semmax Financial Advisors Inc.	unchanged	-	-	1.00	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	reduced	-13.36	-351	165	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	3,723	3,723	-%

Are Funds Buying or Selling ATNF?

Are funds buying ATNF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATNF

No. of Funds

Unveiling 180 Life Sciences Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	1,112,480	SC 13G
Apr 14, 2023	feldmann marc	3.4%	141,747	SC 13D/A
Feb 09, 2022	vanguard index funds	2.95%	1,004,406	SC 13G/A
Feb 09, 2022	vanguard group inc	2.95%	1,004,406	SC 13G/A
Feb 07, 2022	nanchahal jagdeep	4.5%	1,520,564	SC 13G/A
Dec 13, 2021	feldmann marc	8.2%	2,834,930	SC 13D/A
Feb 10, 2021	vanguard group inc	6.54%	1,179,639	SC 13G
Feb 08, 2021	vanguard index funds	5.93%	1,069,400	SC 13G
Dec 31, 2020	bauer ronald	9.2%	2,280,171	SC 13G
Dec 30, 2020	kbl iv sponsor llc	9.03%	2,223,365	SC 13D/A

Recent SEC filings of 180 Life Sciences Corp.

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Apr 24, 2024	EFFECT	EFFECT
Apr 24, 2024	EFFECT	EFFECT
Apr 22, 2024	POS AM	POS AM
Apr 22, 2024	POS AM	POS AM
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	S-8	Employee Benefits Plan
Mar 25, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 12, 2024	3	Insider Trading

Peers (Alternatives to 180 Life Sciences Corp.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

180 Life Sciences Corp. News

Latest updates

180 Life Sciences Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2017Q2
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55,729
Operating Expenses	-58.9%	1,452,488	3,538,187	3,682,980	4,803,845	5,639,896	-	-	-	4,462,055	4,217,476	4,013,169	2,948,303	2,415,973	731,078	934,199	1,566,862	-	-
S&GA Expenses	-100.0%	-	2,433,193	2,762,076	4,008,852	5,053,855	-	-	-	2,490,051	3,519,605	2,678,231	2,542,231	-2,751,361	1,786,122	3,513,039	995,328	4,820,828	-
R&D Expenses	-100.0%	-	972,113	789,441	578,309	503,360	-	-	-	324,668	316,473	246,613	99,899	-	-	351,005	472,862	-	-
EBITDA Margin	49.1%	-857	-1,684	-2,026	-1,771	-1,527	-612	920	-96.51	-777	-1,102	-1,836	-915	-381	-	-	-	-	-
Interest Expenses	4.7%	12,178	11,634	11,606	7,265	8,339	-	-	-	55,574	5,455	12,246	112,933	594,020	82,990	172,498	152,916	-	-
Income Taxes	99.8%	-4,389	-2,345,025	-	-	-	-	-	-	-6,617	-5,612	-5,571	-5,404	-5,253	-5,135	-4,936	-5,102	-227,079	-
Earnings Before Taxes	90.2%	-1,231,494	-12,610,785	-3,680,169	-4,762,078	-22,685,027	-	-	-	1,029,600	18,291,244	-23,464,707	-16,203,989	-7,946,016	-834,553	262,446	-2,386,362	-25,820,100	-
EBT Margin	49.1%	-858	-1,685	-2,027	-1,772	-1,528	-614	918	-99.44	-784	-1,130	-1,867	-952	-420	-	-	-	-	-
Net Income	88.0%	-1,227,105	-10,265,760	-3,680,169	-4,762,078	-21,742,278	-	-	-	1,036,217	18,296,856	-23,459,136	-16,198,585	-7,940,763	-829,418	267,383	-2,381,260	-25,593,021	-
Net Income Margin	50.7%	-768	-1,559	-1,991	-1,736	-1,492	-614	918	-98.76	-783	-1,129	-1,866	-952	-419	-	-	-	-	-
Free Cashflow	-21.7%	-2,160,014	-1,775,475	-3,116,843	-3,869,891	-2,926,755	-3,596,366	-3,531,533	-2,072,931	-5,027,530	-4,002,668	-4,011,185	-6,330,045	-3,216,392	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	6.1%	5,259	4,958	13,667	14,922	19,650	34,336	53,358	59,677	62,714	65,070	56,265	60,112	55,533	11,024	12,626	12,368	51,884	51,573	50,237	66,471	118,437
Current Assets	8.0%	3,640	3,371	2,934	4,196	8,928	6,515	4,647	8,957	11,201	13,634	4,046	8,298	4,015	721	1,186	388	748	901	209	145	271
Cash Equivalents	-25.8%	1,976	2,663	2,009	2,646	6,970	3,589	1,625	5,669	8,225	11,688	1,836	6,053	2,109	33.00	70.00	98.00	83.00	836	110	135	567
Goodwill	-	-	-	-	-	9,063	13,966	12,411	36,324	36,988	36,896	37,561	37,183	36,901	-	-	-	36,423	-	-	-	-
Liabilities	5.5%	5,387	5,107	6,951	7,783	8,306	8,261	10,566	18,773	23,391	27,929	53,549	37,403	25,247	6,277	4,142	7,238	13,314	6,813	5,456	5,203	4,571
Current Liabilities	5.3%	5,063	4,807	4,273	5,122	5,658	4,725	6,966	15,077	19,699	24,225	49,799	33,622	21,421	6,277	4,142	3,213	9,641	2,788	1,431	1,178	546
Shareholder's Equity	-Infinity%	-127	-	6,716	7,140	11,344	26,075	42,791	40,905	39,323	37,141	2,716	22,709	30,287	35,467	35,882	34,747	38,571	5,000	5,000	5,000	5,000
Retained Earnings	-1.0%	-127,343	-126,116	-115,850	-112,170	-107,408	-85,666	-64,179	-67,118	-68,682	-69,718	-88,015	-64,556	-48,357	-7,933	-4,583	852	-37,473	1,360	1,382	1,393	1,161
Additional Paid-In Capital	1.0%	130,117	128,815	125,466	122,195	121,638	115,427	108,786	107,930	107,187	106,154	89,496	86,436	78,005	12,680	9,583	4,147	75,890	3,639	3,618	3,607	3,838
Shares Outstanding	50.8%	535	355	197	197	197	103	90.00	90.00	90.00	80.00	83.00	74.00	69.00	-	-	-	-	-	-	-	-
Float	-	-	-	5,851	-	25,377	-	25,377	-	271,883	-	20,792	-	-	-	-	-	-	-	50,159	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-21.7%	-2,160	-1,775	-3,116	-3,869	-2,926	-3,596	-3,531	-2,072	-5,027	-4,002	-4,011	-6,330	-3,216	-53.97	-192	-409	-2,158	-216	-636	-307	-192
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,506	-	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	12,878	973	707	-66.86	-69,979	-388	16,654	53,005	144
Cashflow From Financing	-40.0%	1,468	2,447	2,462	-469	6,396	5,488	-494	-515	1,549	13,729	-228	10,363	-9,225	147	12.00	333	-38,962	1,330	-16,041	-52,834	-199

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATNF Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses:
Total Operating Expenses	$ 13,477,500	$ 17,897,965
Loss From Operations	(13,477,500)	(17,897,965)
Other Income (Expenses):
Other income	21,074
Interest expense	(44,828)	(28,175)
Interest income – related parties		1,508
Loss on goodwill impairment		(33,547,278)
Loss on IP R&D impairment	(9,063,000)	(3,342,084)
Change in fair value of derivative liabilities	75,323	15,144,986
Gain on settlement of accrued liability	204,405
Total Other Expense, Net	(8,807,026)	(21,771,043)
Net Loss Before Income Taxes	(22,284,526)	(39,669,008)
Income tax benefit	2,349,414	942,749
Net Loss	(19,935,112)	(38,726,259)
Other Comprehensive Loss:
Foreign currency translation adjustments	(15,816)	(3,702,963)
Total Comprehensive Loss	$ (19,950,928)	$ (42,429,222)
Basic Net Loss per Common Share (in Dollars per share)	$ (52.59)	$ (387.18)
Weighted Average Number of Common Shares Outstanding: (in Shares)	379,089	100,021
Non-Related Party
Operating Expenses:
Research and development	$ 2,303,751	$ 2,191,834
General and administrative	10,646,417	15,459,788
Related Party
Operating Expenses:
Research and development	480,777	240,731
General and administrative	$ 46,555	$ 5,612

ATNF Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 1,975,799	$ 6,970,110
Prepaid expenses and other current assets	1,664,107	1,958,280
Total Current Assets	3,639,906	8,928,390
Intangible assets, net	1,619,570	1,658,858
In-process research and development		9,063,000
Total Assets	5,259,476	19,650,248
Current Liabilities:
Accounts payable	1,892,611	1,801,210
Accrued expenses	1,869,814	2,284,516
Loans payable - current portion	1,034,124	1,308,516
Derivative liabilities	58	75,381
Total Current Liabilities	5,062,616	5,657,782
Loans payable - noncurrent portion	19,936	31,189
Deferred tax liability	304,657	2,617,359
Total Liabilities	5,387,209	8,306,330
Commitments and contingencies (Note 9)
Stockholders’ (Deficit) Equity:
Preferred stock value
Common stock, $0.0001 par value; 100,000,000 shares authorized; 534,719 and 197,209 shares issued and outstanding at December 31, 2023 and 2022, respectively	54	20
Additional paid-in capital	130,117,209	121,637,966
Accumulated other comprehensive income	(2,901,339)	(2,885,523)
Accumulated deficit	(127,343,657)	(107,408,545)
Total Stockholders’ (Deficit) Equity	(127,733)	11,343,918
Total Liabilities and Stockholders’ Equity	5,259,476	19,650,248
Class C Preferred Stock
Stockholders’ (Deficit) Equity:
Preferred stock value
Class K Preferred Stock
Stockholders’ (Deficit) Equity:
Preferred stock value
Related Party
Current Liabilities:
Accounts payable – related parties	266,009
Accrued expenses - related parties		$ 188,159

About 180 Life Sciences Corp.

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

CEO	Dr. James N. Woody M.D., Ph.D.
WEBSITE	https://180lifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	5

180 Life Sciences Corp. Frequently Asked Questions

What is the ticker symbol for 180 Life Sciences Corp.? What does ATNF stand for in stocks?

ATNF is the stock ticker symbol of 180 Life Sciences Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 180 Life Sciences Corp. (ATNF)?

As of Thu May 02 2024, market cap of 180 Life Sciences Corp. is 1.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers. The fair value of 180 Life Sciences Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 180 Life Sciences Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATNF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 180 Life Sciences Corp. a good stock to buy?

The fair value guage provides a quick view whether ATNF is over valued or under valued. Whether 180 Life Sciences Corp. is cheap or expensive depends on the assumptions which impact 180 Life Sciences Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNF.

What is 180 Life Sciences Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, ATNF's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 64.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNF PE ratio will change depending on the future growth rate expectations of investors.